http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111808193-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 |
| filingDate | 2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111808193-B |
| titleOfInvention | Nanobody capable of binding human CD38 and application thereof |
| abstract | The invention relates to a polypeptide capable of binding to human CD38, which comprises 3 complementarity determining regions CDR1-3, wherein the sequence of CDR1 is or comprises one of the sequences shown in SEQ ID NO. 1-36, the sequence of CDR2 is or comprises one of the sequences shown in SEQ ID NO. 37-72, and the sequence of CDR3 is or comprises one of the sequences shown in SEQ ID NO. 73-111. The invention carries out nano antibody drug development and diagnostic reagent development aiming at hematopoietic system malignant tumor, and selects the nano antibody VHH specifically combined with CD38 by preparing CD38 protein, immune alpaca, platform technology for displaying nano monoclonal antibody by using phage library, etc., identifies the CDR sequence thereof, and constructs humanized antibody C38 NB; and the efficacy of C38NB in treating multiple myeloma is evaluated in vivo by using a humanized mouse model. The invention provides a potential new nano-antibody medicament and a new cell therapy medicament for clinical treatment of malignant tumors of the hematopoietic system, and provides a corresponding detection reagent for diagnosis of malignant tumors of the hematopoietic system. |
| priorityDate | 2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 435.